Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Hydromorphone · Dilaudid, Exalgo

Small molecule · Agonist of mu-opioid receptor (OPRM1) · developed by Specgx Llc

Approved FDA, Mar 2010
1 Registered trials

What is Hydromorphone?

Hydromorphone is a semi-synthetic opioid agonist that binds relatively selectively to the mu-opioid receptor, producing analgesia. It is used for management of severe pain and is also studied in opioid use disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Dilaudid, Exalgo, Hydromorphone Hydrochloride, dihydromorphinone
Drug type
Small molecule
Targets
mu-opioid receptor (OPRM1)
Mechanism
Agonist of mu-opioid receptor (OPRM1)
Pathways
G-protein signaling, adenylate cyclase/cAMP inhibition, potassium channel activation, calcium channel inhibition
Therapy area
Psychiatry
Developer
Specgx Llc
In trials of
INDV
FDA status
Approved as Dilaudid, Exalgo, Hydromorphone Hydrochloride (March 1, 2010), NDA021217 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 15, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02044094 Phase 2 Opioid Use Disorder Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Opioid Use Disorder

Other drugs acting on OPRM1

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.